Citigroup Inc. Has $3.94 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Citigroup Inc. boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 125.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 168,277 shares of the biopharmaceutical company's stock after buying an additional 93,730 shares during the period. Citigroup Inc. owned approximately 0.11% of TG Therapeutics worth $3,936,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new position in TG Therapeutics during the third quarter valued at $759,000. Segall Bryant & Hamill LLC purchased a new position in TG Therapeutics in the third quarter valued at about $1,225,000. Principal Financial Group Inc. grew its stake in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in TG Therapeutics in the second quarter valued at about $8,698,000. Finally, Marshall Wace LLP purchased a new position in TG Therapeutics in the second quarter valued at about $36,501,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Price Performance

Shares of TGTX traded up $0.49 during mid-day trading on Wednesday, reaching $33.88. The company had a trading volume of 1,717,699 shares, compared to its average volume of 3,656,192. The company has a market capitalization of $5.27 billion, a P/E ratio of -337.50 and a beta of 2.25. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84. The company's 50-day moving average is $27.03 and its 200-day moving average is $22.56. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm's revenue was down 49.4% on a year-over-year basis. During the same quarter last year, the company earned $0.73 earnings per share. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. B. Riley upped their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. HC Wainwright boosted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.